Related Experiment Video
Updated: Jun 19, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The new oral anticoagulants
David Garcia1, Edward Libby, Mark A Crowther
1University of New Mexico, MSC08-4630, 900 Camino de Salud NE, Albuquerque, NM 87131-0001. davgarcia@salud.unm.edu
Blood
|November 3, 2009
Summary
New oral anticoagulants like apixaban, dabigatran, and rivaroxaban offer alternatives to vitamin K antagonists for preventing and treating thrombotic diseases. These novel agents are being investigated for various conditions, including atrial fibrillation and venous thromboembolism.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Vitamin K antagonists (VKAs) have been the sole long-term oral anticoagulants since the 1940s.
- Despite VKA effectiveness, issues like dose variability, narrow therapeutic index, and drug/diet interactions necessitate alternatives.
- The search for safer and more predictable oral anticoagulants is ongoing.
Purpose of the Study:
- To review clinical trial data for three novel oral anticoagulants: apixaban, dabigatran, and rivaroxaban.
- To summarize the current status and potential applications of these emerging anticoagulant agents.
- To provide an overview of the latest research on new oral anticoagulants.
Main Methods:
- Systematic review of published clinical trial data.
- Focus on trials involving apixaban, dabigatran, and rivaroxaban.
- Analysis of data relevant to efficacy and safety in thrombotic disease prevention and treatment.
Main Results:
- Apixaban, dabigatran, and rivaroxaban are in late-stage development.
- These novel agents are being studied for venous thromboembolism, acute coronary syndromes, and stroke prevention in atrial fibrillation.
- Published data indicate potential efficacy and varying safety profiles for these new oral anticoagulants.
Conclusions:
- Novel oral anticoagulants represent a significant advancement in anticoagulant therapy.
- Apixaban, dabigatran, and rivaroxaban show promise as alternatives to vitamin K antagonists.
- Further research and clinical data are crucial for establishing the role of these agents in routine practice.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...